StoxMankind Pharma vs Aurobindo Pharma: share price & financials comparison
NSE: MANKIND vs AUROPHARMA · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Mankind Pharma vs Aurobindo Pharma at a glance
Mankind Pharma (MANKIND) has a market capitalisation of ₹1,04,902 Cr, against ₹1,03,572 Cr for Aurobindo Pharma (AUROPHARMA). Over the past year Aurobindo Pharma has returned +61.9%, compared with +3.9% for Mankind Pharma. On valuation, Aurobindo Pharma trades at a lower P/E of 26.0 versus 46.7. Mankind Pharma earns a higher return on equity (12.8% vs 10.1%). Mankind Pharma comes out ahead on profitability and growth. Aurobindo Pharma comes out ahead on size, valuation, financial health, momentum and technicals. Across the scored metrics below, Mankind Pharma leads on 5 and Aurobindo Pharma on 11. On StoxGud's 10-point checklist, Mankind Pharma scores 7/10 and Aurobindo Pharma scores 9/10.
| Metric | Mankind Pharma | Aurobindo Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹1,04,902 Cr | ₹1,03,572 Cr |
| Revenue (latest FY) | ₹14,278 Cr | ₹33,653 Cr |
| Net profit (latest FY) | ₹1,913 Cr | ₹3,505 Cr |
| Valuation | ||
| P/E | 46.7 | 26.0 |
| P/B | 5.97 | 2.63 |
| Dividend yield | 0.04% | 0.22% |
| Profitability | ||
| Return on equity | 12.8% | 10.1% |
| Net profit margin | 14.6% | 10.8% |
| Operating margin | 26.5% | 20.5% |
| Growth | ||
| Revenue growth (YoY) | +17.3% | +23.9% |
| Net profit growth (YoY) | +39.1% | +32.7% |
| Revenue CAGR (multi-year) | +17.7% | +6.3% |
| Financial health | ||
| Debt to equity | 0.31 | 0.21 |
| Momentum | ||
| 1-month return | +1.6% | +7.0% |
| 1-year return | +3.9% | +61.9% |
| 3-year CAGR | +13.0% | +27.2% |
| 5-year CAGR | — | +21.8% |
| 10-year CAGR | — | +8.9% |
| Distance from 52W high | -3.0% | +0.0% |
| Technicals | ||
| RSI (14) | 72 | 67 |
| Price vs 200-day avg | +9.5% | +22.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Mankind Pharma | Aurobindo Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 7/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Mankind Pharma or Aurobindo Pharma?
Mankind Pharma has a market cap of ₹1,04,902 Cr and Aurobindo Pharma has a market cap of ₹1,03,572 Cr as of 06 Nov 2026.
Which has a lower P/E, Mankind Pharma or Aurobindo Pharma?
Aurobindo Pharma has the lower P/E: Mankind Pharma trades at 46.7 and Aurobindo Pharma at 26.0.
Which gave better returns in the last year, Mankind Pharma or Aurobindo Pharma?
Aurobindo Pharma did better: Mankind Pharma returned +3.9% and Aurobindo Pharma returned +61.9% over one year.
Is Mankind Pharma or Aurobindo Pharma a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Mankind Pharma scores 7/10 and Aurobindo Pharma scores 9/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.